Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the literature on classic and more recent anti-tubulin agents, providing an insight into their mechanisms of action and their use in the treatment of lymphoma.

中文翻译：

---

抗微管蛋白药物治疗淋巴瘤患者的概述。

由于对微管动力学的干扰，抗微管蛋白剂构成一类在实体瘤和血液系统恶性肿瘤中均具有广泛活性的化合物。由于微管在有丝分裂纺锤体的调控中起着关键作用，因此对其功能的干扰通常会导致细胞分裂受阻，阻滞在有丝分裂的中期/后期交界处，随后导致细胞凋亡。这解释了为什么微管蛋白结合剂（TBA）在癌症患者中表现出极高的活性。几种抗微管蛋白药物可单独或联合化疗方案用于淋巴瘤患者的治疗。本文回顾了有关经典和最新抗微管蛋白药物的文献，以深入了解其作用机理及其在淋巴瘤治疗中的用途。